CAS 1197376-85-4

Capmatinib dihydrochloride

Description:

Capmatinib dihydrochloride is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with MET exon 14 alterations. As a dihydrochloride salt, it enhances the solubility and stability of the active compound, capmatinib. The substance functions by selectively inhibiting the MET receptor tyrosine kinase, which plays a crucial role in tumor growth and metastasis. Capmatinib dihydrochloride is characterized by its ability to penetrate tissues effectively and its specificity for MET, minimizing off-target effects. It is typically administered orally and has undergone extensive clinical trials to establish its efficacy and safety profile. Common side effects may include gastrointestinal disturbances, fatigue, and liver enzyme elevations. The compound's pharmacokinetics indicate a moderate half-life, necessitating careful dosing regimens to maintain therapeutic levels. Overall, capmatinib dihydrochloride represents a targeted therapeutic approach in oncology, reflecting advancements in personalized medicine.

Benzamide, 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-, hydrochloride (1:2)

CAS: 1197376-85-4

Formula: C₂₃H₁₉Cl₂FN₆O

Purity: 95%

Color and Shape: Solid

Molecular weight: 485.3410

Ref: IN-DA000PKV

Capmatinib 2HCl

CAS: 1197376-85-4

Capmatinib 2HCl

Purity: ≥98%

Molecular weight: 485.34g/mol

Ref: 54-BUP12769

Capmatinib 2HCl

CAS: 1197376-85-4

Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.

Formula: C₂₃H₁₉Cl₂FN₆O

Purity: 98.80%

Color and Shape: Solid

Molecular weight: 485.34

Ref: TM-T4260